Clinical Trial Update: Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update describes an ongoing Phase 2/Phase 3 study sponsored by Han Xu evaluating raloxifene with respect to single nucleotide polymorphisms …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Raloxifene (raloxifene)

Snippet

Sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair | Conditions: Breast Cancer | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING